June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Novel USH2A gene mutations and USH phenocopies described as a part of prospective Russian Usher syndrome clinical trial
Author Affiliations & Notes
  • Marianna E Weener
    Research and Development, Oftalmic LLC, Moscow, Russian Federation
  • Tatiana A Avanesova
    Ophthalmology, Central Clinical Hospital under President Affairs, Moscow, Russian Federation
  • Varvara A Shibanova
    Russian patient organization "LookToSee", Moscow, Russian Federation
  • Tatiana G Markova
    FGBU Rossijskij naucno-kliniceskij centr audiologii i sluhoprotezirovania Federal'nogo mediko-biologiceskogo agentstva Rossii, Moskva, Moskva, Russian Federation
    Research and Development, Oftalmic LLC, Moscow, Russian Federation
  • Footnotes
    Commercial Relationships   Marianna Weener None; Tatiana Avanesova None; Varvara Shibanova None; Tatiana Markova None
  • Footnotes
    Support  ANO “Sensor technology for deafblind” and Deaf-Blind Support Foundation Connection
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 622 – A0337. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marianna E Weener, Tatiana A Avanesova, Varvara A Shibanova, Tatiana G Markova; Novel USH2A gene mutations and USH phenocopies described as a part of prospective Russian Usher syndrome clinical trial. Invest. Ophthalmol. Vis. Sci. 2022;63(7):622 – A0337.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Usher syndrome (USH) is a rare genetic autosomal recessive (AR) disorder characterized by sensorineural hearing loss and retinitis pigmentosa. We performed prospective observational natural history clinical trial to clarify genotype-phenotype correlation of Usher syndrome patients in Russia for possible further treatment application

Methods : 118 syndromic RP patients with hearing loss of AR and sporadic inheritance were included under NCT03901391 and NCT03319524 protocols. Complete ophthalmic and audiology examinations were conducted in all the study subjects. DNA samples were extracted from patients’ peripheral blood for whole exome sequencing (WES) analysis. Sanger sequencing was conducted for validating the identified mutations and cosegregation pattern in the families, MLPA was done for deletions borders clarification.

Results : USH patient group data is in Table 1. USH1 patients with biallelic mutations in MYO7A (14 cases), USH1C (1 case), CDH23 (2 cases), PCDH15 (2 cases) and CIB2 (1 case). USH2 patients with biallelic mutations in USH2A (71 cases), 15 of them are newly reported mutations in USH2A gene and are provided in Table 2. 7 patients had W3955X USH2A mutation – 3 homozygous and 4 – in compound heterozygous state with another confirmed pathogenic mutation, which are considered to be of founder effect from eastern Europe, one of the patients had deletion of 38 exon of USH2A c.7121-?_7303+? del, mutations in GPR98 (1 case), DFNB31 (2 cases). In 6 patients biallelic CLRN1 gene mutations were confirmed of USH3 group, 3 of those patients have known ancestors from Baltic region including Finland. Partially solved cases included USH2A: 1 heterozygous mutation, no second mutation found (3 cases), POC1B (1 case), EYS (1 case) – two compound heterozygous mutations, PRGR hemizygous mutation – but no genetic causes of hearing loss is found in these cases. GJB2 hearing loss genetically confirmed, but no genetic causes of vision loss found (3 cases). There were USH phenotype patients with confirmed another genetic disease: NIPBL (Cornelia de Lange syndrome 1), LOXHD1 (Deafness, autosomal recessive 77), PRGR (X-linked retinitis pigmentosa), PEX6 (Zellweger spectrum disorder). No any mutations found in 4 USH patients.

Conclusions : This study clarified main genetic causes of Usher syndrome and its phenocopies in Russian patients, 15 novelvariants in USH2A gene were identified.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×